LifeStance Health Files 8-K: Secondary Offering and 2.0M-Share Repurchase

What Happened

• LifeStance Health Group, Inc. announced an underwritten offering that closed on September 11, 2026. Barclays Capital Inc. acted as the underwriter for the transaction under the company’s Form S-3 registration (File No. 333-279585).
• Selling stockholders sold 22,250,000 existing shares of LifeStance common stock. Under the Underwriting Agreement, the company agreed to purchase 2,000,000 of those shares from the underwriter at the same price paid by the underwriter to the selling stockholders. The company did not receive any proceeds from the offering. Ropes & Gray LLP provided a legal opinion for the transaction (filed as Exhibit 5.1).

Key Details

• Closing date: September 11, 2026.
• Total shares sold by selling stockholders: 22,250,000 shares of common stock.
• Company repurchased: 2,000,000 shares from the underwriter at the underwriter’s purchase price; underwriter received no extra compensation for those repurchased shares.
• Company received no proceeds from the overall offering (all primary shares were sold by selling stockholders).

Why It Matters

• No new capital raised: Because all 22.25M shares were sold by existing selling stockholders, the company did not raise cash from outside investors through this offering.
• Share count impact: The company repurchased 2.0M shares — this reduces shares held by selling stockholders and could affect the company’s outstanding share count and per‑share metrics depending on whether those repurchased shares are retired or held as treasury (the filing does not state disposition).
• Governance/legal: The transaction was documented by an Underwriting Agreement with Barclays and supported by legal counsel (Ropes & Gray), indicating the offering and repurchase followed customary procedures.

Investors should note the transaction’s dates, the repurchase amount, and that the filing does not indicate whether repurchased shares will be retired or held in treasury; check future filings for any effect on outstanding shares or cash balances.